The Eloxatin®-based regimen (FOLFOX4) significantly improved progression free survival when given before and after surgery in patients with resectable liver metastases from colorectal cancer
Contact:Sanofi-aventis EORTCSalah Mahyaoui Nicole Heine+ 33 6 73 68 78 88 + 32 478 55 98 36Anne Bancillon nicole.heine@eortc.be+ 33 6 86 31 03 89The Eloxatin®-based regimen (FOLFOX4) significantly improved progression free survival when given beforeand after surgery in patients with resectable liver metastases from colorectal cancer- Presentation at ASCO Plenary Session ReportsEORTC 40983 (EPOC) Intergroup Study Results -Paris, France - June 4, 2007 – Results of the randomized phase III EORTC 40983 Intergroup study, or EPOC (Eloxatin Peri-Operative Chemotherapy) study,